Alessandro Tomelleri
Overview
Explore the profile of Alessandro Tomelleri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
1671
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bergonzi G, Campochiaro C, Tomelleri A, Del Poggio A, Bonacchi R, Ferre L, et al.
Curr Res Transl Med
. 2025 Mar;
73(3):103505.
PMID: 40086416
No abstract available.
2.
Caponcello M, Navarro P, Bonazzetti C, Campoli C, Savoldi A, Gentilotti E, et al.
Clin Microbiol Infect
. 2025 Mar;
PMID: 40049395
Introduction: The clinical management of COVID-19 in immunocompromised patients remains a challenge. The aim of this work was to develop a consensus to establish recommendations for the clinical, diagnostic and...
3.
Vitale A, Caggiano V, Leone F, Hinojosa-Azaola A, Martin-Nares E, Guaracha-Basanez G, et al.
Front Pharmacol
. 2025 Mar;
16:1462254.
PMID: 40046741
Background: VEXAS syndrome, a recently identified systemic autoinflammatory disorder, poses new diagnostic and management challenges. Based on experience with other autoinflammatory diseases, anti-interleukin (IL)-1, anti-IL-6, anti-tumor necrosis factor (TNF) biotechnological...
4.
Zorc R, Redmond C, Sylvester M, Maclean M, Yamamoto de Almeida L, Quinn K, et al.
Ann Rheum Dis
. 2025 Feb;
PMID: 40000263
Objectives: The study objective was to determine if a common single nucleotide polymorphism in the interleukin 6 (IL-6) receptor (rs2228145, p.Asp358Ala) predicted treatment response to tocilizumab in giant cell arteritis...
5.
Tomelleri A, Dejaco C, Bond M
Reumatismo
. 2025 Feb;
PMID: 39945417
Inflammatory rheumatic and musculoskeletal diseases, including systemic vasculitis, increase the risk of infection due to immunosuppressive treatments and disease-related immune dysfunction. In this viewpoint, we focused on patients with antineutrophil...
6.
Campochiaro C, Tomelleri A, Catamero F, Pegoraro F, Vaglio A, Dagna L
Rheumatology (Oxford)
. 2025 Jan;
PMID: 39814074
Objective: Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis that exhibits a wide spectrum of clinical manifestations. The recent identification of activating mutations in the MAPK-ERK pathway in patients...
7.
Tomelleri A, Farina N, Dagna L
Eur J Intern Med
. 2024 Dec;
132:37-39.
PMID: 39658397
No abstract available.
8.
Ruscitti P, Di Cola I, Vitale A, Caggiano V, Palumbo P, Di Cesare E, et al.
J Rheumatol
. 2024 Nov;
52(3):226-233.
PMID: 39547690
Objective: We aimed to (1) evaluate the cardiac involvement, with a focus on myocarditis, in patients with Still disease included in the multicenter Autoinflammatory Disease Alliance (AIDA) Network Still disease...
9.
Gurnari C, Galossi E, Lumia E, Piciocchi A, Divona M, Casciani E, et al.
Br J Haematol
. 2024 Nov;
206(1):331-336.
PMID: 39533868
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) is a haemato-inflammatory syndrome genetically defined by somatic mutations in the X-linked UBA1 gene, typically Val/Thr/Leu substitutions at the Met41 hotspot. Clinical manifestations...
10.
Bond M, Tomelleri A, Reatini M, Campochiaro C, Cattani G, Dagna L, et al.
Arthritis Care Res (Hoboken)
. 2024 Jul;
77(1):30-37.
PMID: 39014894
Objective: The aim of this study was to investigate the association between exposure to particulate matter with an aerodynamic diameter ≤10 μm (PM) and the development of giant cell arteritis...